ETNB News and Press, 89bio Inc. From 06/28/22

- Trial met primary endpoint demonstrating statistically significant and clinically meaningful reductions across all doses (63% at the 27mg QW dose; p<0.001) in triglycerides (TG) from baseline; results were consistent in patients on or not on background therapy - - Observed ...

SAN FRANCISCO, June 21, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced additional pegozafermin ...

89bio (NASDAQ:ETNB), a biotech known for its liver disease studies, is trading higher in the pre-market Thursday after Raymond James upgraded the stock to Strong Buy from Outperform, citing its potential in a lipid disorder called severe hypertriglyceridemia (SHTG). The company is advancing m...

89bio press release (NASDAQ:ETNB): Q1 GAAP EPS of -$1.26 beats by $0.03. As of March 31, 2022, 89bio had cash, cash equivalents, and short-term investments of $126.1 million. Based upon current projections, 89bio believes it has sufficient cash to fund operations into the second half of 2023....

- ENTRIGUE Phase 2 trial of pegozafermin in severe hypertriglyceridemia (SHTG) patients remains on track with topline data expected in the second quarter of 2022 - - ENLIVEN Phase 2b NASH trial enrollment completion expected in the third quarter of 2022 followed by topline dat...

SAN FRANCISCO, April 26, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that it will host a key...

89bio press release (NASDAQ:ETNB): Q4 GAAP EPS of -$1.30 misses by $0.03. As of December 31, 2021, 89bio had cash, cash equivalents, and short-term investments totaling $150.7 million compared to $204.7 million as of December 31, 2020. For further details see: 89bio GAAP EPS of -$1.30 m...

– Reported positive topline results from cohort 7 in the Phase 1b/2a trial including data from new analyses demonstrating the promising therapeutic utility of pegozafermin for the treatment of NASH – – ENLIVEN Phase 2b NASH trial on track for ...

- Interim data from NL-201 Phase 1 trial for patients with relapsed and refractory solid tumors anticipated in the second half of 2022 – - $142.5 million in cash and cash equivalents expected to provide runway into the second half of 2023 – - Appointment of R...

The following slide deck was published by 89bio, Inc. in conjunction with this event. For further details see: 89bio (ETNB) Presents At Global Healthcare Virtual Conference - Slideshow